Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F9 | P00740 | 2/20 | 0.42 |
| ▸ | F11 | P03951 | 8/20 | 0.39 |
| ▸ | KLK1 | P06870 | 5/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1894210 | 0.84 | ANO1 (0.51) | MEN1KMT2A | |
| SCHEMBL12756682 | 0.80 | PPARG (0.41) | MALT1TP53MAPTMEN1KMT2A | |
| SCHEMBL12756673 | 0.79 | MEN1 (0.44) | MAPK1L3MBTL1MAPTMEN1KMT2A | |
| SCHEMBL1493891 | 0.79 | ANO1 (0.39) | MALT1TP53MAPTMEN1KMT2A | |
| SCHEMBL12756663 | 0.76 | ANO1 (0.38) | MALT1TP53MAPTMEN1KMT2A | |
| SCHEMBL12830003 | 0.73 | TP53 (0.49) | TP53MAPTMEN1KMT2APOLB | |
| SCHEMBL12756632 | 0.73 | LMNA (0.50) | MALT1MAPK1L3MBTL1MEN1KMT2A | |
| SCHEMBL12830007 | 0.72 | CNR1 (0.57) | MAPTMEN1KMT2A | |
| SCHEMBL1490453 | 0.72 | KCNQ2 (0.42) | L3MBTL1MAPTMEN1KMT2APOLB | |
| SCHEMBL12830739 | 0.71 | ANO1 (0.43) | MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140051711-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2014-02-20 | — | — | US | disclosed |
| WO-2011034962-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2011-03-24 | — | — | WO | disclosed |
| US-20110065724-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051711-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | F9 4819/4885F11 4754/4885KLK1 4851/4885 |
| US-20110065724-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | F9 4819/4885F11 4754/4885KLK1 4851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.